I've already said bye bye to tabalumab a year
ago as I had been very disappointed with the data shown during the past two
years, but here we still are. Tabalumab (LY2127399) is a human IgG4 monoclonal
antibody against B-cell activating factor (BAFF). And there have been two
abstracts/posters.
J.S. Smolen and colleagues presented [FRI0326]:
"EFFICACY AND SAFETY OF TABALUMAB, AN ANTI-B CELL ACTIVATING FACTOR
MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN
INADEQUATE RESPONSE TO METHOTREXATE THERAPY: RESULTS FROM A PHASE 3
MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY". Conclusions: "In this phase
3 study, tabalumab demonstrated no clinical efficacy despite evidence of
biologic activity. There were no differences in reports of AEs of interest and
no new or unexpected safety findings for RA pts receiving tabalumab."
M. Schiff and colleagues presented [AB0438]:
"EFFICACY AND SAFETY OF TABALUMAB, AN ANTI-B CELL ACTIVATING FACTOR
MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN
INADEQUATE RESPONSE TO TNF-ALPHA INHIBITORS: RESULTS FROM A PHASE 3
MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY". Conclusions: "In this phase
3 study, tabalumab demonstrated no clinical efficacy despite evidence of
biologic activity, suggesting that targeting BAFF may not be a viable
therapeutic approach to treating pts with RA. There were no differences in
reports of infection or allergic/hypersensitivity events and no new or
unexpected safety findings for RA pts receiving tabalumab."
In the case of tabalumab I hate to
be proven right: it's bye bye tabalumab!
Link:
No comments:
Post a Comment